Peroxisome proliferator-activated receptor (PPAR)-γ positively controls and PPARα negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARβ/δ via mutual control of PPAR expression levels

Molecular Pharmacology

Volumn 76, Issue 2, 2009, Pages 414-424

  Aleshin, Stepan ^a,b   Grabeklis, Sevil ^a,b   Hanck, Theodor ^a   Sergeeva, Marina ^b   Reiser, Georg ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; CIGLITAZONE; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME REGULATION; GENE CONTROL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RAT;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN; BUTYRIC ACIDS; CELLS, CULTURED; CYCLOOXYGENASE 2; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIAL FIBRILLARY ACIDIC PROTEIN; LIPOPOLYSACCHARIDES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHENOXYACETATES; PHENYLUREA COMPOUNDS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PPAR-BETA; PROTEIN ISOFORMS; RATS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 67650792427     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.056010     Document Type: Article

References (40)

1. Aid S, Langenbach R, and Bosetti F (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation 5:17. (Pubitemid 351803159)
2. Balakumar P, Rose M, Ganti SS, Krishan P, and Singh M (2007) PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 56:91-98. (Pubitemid 47304493)
3. Bensinger SJ and Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470-477.
4. Bernardo A and Minghetti L (2008) Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res 2008:864140. (Pubitemid 351712915)
5. Bordet R, Ouk T, Petrault O, Gelé P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346. (Pubitemid 46769051)
6. Collino M, Patel NS, and Thiemermann C (2008) PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2:179-197. (Pubitemid 351859071)
7. Consilvio C, Vincent AM, and Feldman EL (2004) Neuroinflammation, COX-2, and ALS - a dual role? Exp Neurol 187:1-10. (Pubitemid 38470006)
8. Cristiano L, Cimini A, Moreno S, Ragnelli AM, and Paola Cerù M (2005) Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures. Neuroscience 131:577-587. (Pubitemid 40261214)
9. Culman J, Zhao Y, Gohlke P, and Herdegen T (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28:244-249. (Pubitemid 46661003)
10. Drew PD, Xu J, Storer PD, Chavis JA, and Racke MK (2006) Peroxisome proliferatoractivated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 49:183-189. (Pubitemid 43867076)
11. Glinghammar B, Skogsberg J, Hamsten A, and Ehrenborg E (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308:361-368. (Pubitemid 36937188)
12. Grau R, Punzón C, Fresno M, and Iñiguez MA (2006) Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J 395:81-88.
13. Heales SJ, Lam AA, Duncan AJ, and Land JM (2004) Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 29:513-519. (Pubitemid 38295002)
14. Heneka MT and Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771:1031-1045.
15. Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, Hsi LC, and Eling TE (2001) Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 267:73-80. (Pubitemid 32579142)
16. Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, Mihara K, Moriguchi A, and Matsuoka N (2007) Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo. J Pharmacol Exp Ther 320:1087-1096. (Pubitemid 46294065)
17. Kang YJ, Mbonye UR, DeLong CJ, Wada M, and Smith WL (2007) Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 46:108-125. (Pubitemid 46661865)
18. Kapadia R, Yi JH, and Vemuganti R (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 13:1813-1826. (Pubitemid 351599735)
19. Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, and BronfmanM(2008) A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. J Cell Physiol 217:367-376.
20. Lemay DG and Hwang DH (2006) Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 47:1583-1587.
21. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, and Perez-Castillo A (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor γ activation. J Biol Chem 280:21453-21462. (Pubitemid 40805710)
22. Matsusue K, Peters JM, and Gonzalez FJ (2004) PPARbeta/delta potentiates PPAR-gamma-stimulated adipocyte differentiation. FASEB J 18:1477-1479. (Pubitemid 39561620)
23. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58:726-741. (Pubitemid 44833742)
24. Michalik L and Wahli W (2008) PPARs mediate lipid signaling in inflammation and cancer. PPAR Res 2008:134059.
25. Pahan K, Jana M, Liu X, Taylor BS, Wood C, and Fischer SM (2002) Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem 277:45984-45991. (Pubitemid 35417583)
26. Park EJ, Park SY, Joe EH, and Jou I (2003) 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278:14747-14752.
27. Peters JM, Hollingshead HE, and Gonzalez FJ (2008) Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) 115:107-127.
28. Ricote M and Glass CK (2007) PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771:926-935.
29. Saluja I, Granneman JG, and Skoff RP (2001) PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33:191-204. (Pubitemid 32219128)
30. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, Vignon F, Nicolas JC, and Balaguer P (2005) Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem 344:8-15. (Pubitemid 41569372)
31. Shi Y, Hon M, and Evans RM (2002) The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A 99:2613-2618. (Pubitemid 34240509)
32. 2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in prostanoid production in brain: perspectives for protection in neuroinflammation. Int J Dev Neurosci 22:551-557.
33. Strokin M, Sergeeva M, and Reiser G (2007) Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A2. J Neurochem 102:1771-1782. (Pubitemid 47329261)
34. Tzeng SF, Hsiao HY, and Mak OT (2005) Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 4:335-340. (Pubitemid 40873121)
35. 2 inhibits the synthesis of the acute phase protein SIP24 in cartilage: involvement of COX-2 in resolution of inflammation. J Cell Physiol 217:433-441.
36. Xu J, Chavis JA, Racke MK, and Drew PD (2006a) Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176:95-105. (Pubitemid 44080345)
37. Xu J and Drew PD (2007) Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 178:1904-1913. (Pubitemid 46154663)
38. 2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res 66:11859-11868.
39. Zhang Q, Seltmann H, Zouboulis CC, and Konger RL (2006) Involvement of PPAR-gamma in oxidative stress-mediated prostaglandin E2 production in SZ95 human sebaceous gland cells. J Invest Dermatol 126:42-48. (Pubitemid 43336092)
40. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, and Shureiqi I (2006) Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25:1225-1241. (Pubitemid 43297937)